AGEN Logo

Agenus Inc. (AGEN) 

NASDAQ
Market Cap
$91.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
158 of 776
Rank in Industry
99 of 433

Largest Insider Buys in Sector

AGEN Stock Price History Chart

AGEN Stock Performance

About Agenus Inc.

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical …

Insider Activity of Agenus Inc.

Over the last 12 months, insiders at Agenus Inc. have bought $343,050 and sold $0 worth of Agenus Inc. stock.

On average, over the past 5 years, insiders at Agenus Inc. have bought $343,050 and sold $1.46M worth of stock each year.

Highest buying activity among insiders over the last 12 months: ARMEN GARO H (See Remarks) — $648,100. WIINBERG ULF (director) — $38,000.

The last purchase of 500,000 shares for transaction amount of $324,050 was made by ARMEN GARO H (See Remarks) on 2024‑02‑15.

List of Insider Buy and Sell Transactions, Agenus Inc.

2024-02-15PurchaseSee Remarks
500,000
0.0915%
$0.65$324,050-22.17%
2023-11-15Purchasedirector
25,000
0.0067%
$0.76$19,000-18.81%
2022-01-06SaleChief Medical Officer
38,679
0.0149%
$3.06$118,346-16.94%
2021-09-13SaleChairman and CEO
82,107
0.0357%
$6.50$533,696-56.93%
2021-09-10SalePFO & PAO
11,120
0.0047%
$6.50$72,280-57.69%
2020-06-17Sale10 percent owner
283,840
0.1709%
$3.66$1.04M+4.04%
2020-06-16Sale10 percent owner
144,160
0.0877%
$3.66$528,015+4.63%
2020-06-15Sale10 percent owner
384,025
0.2247%
$3.57$1.37M+3.05%
2020-06-12Sale10 percent owner
9,100
0.0055%
$3.58$32,556+6.30%
2020-06-11Sale10 percent owner
183,875
0.1139%
$3.77$692,786+3.20%
2017-12-12SaleChief Legal Officer
16,716
0.0174%
$3.46$57,842-16.91%
2017-12-12SaleVP, Finance
11,220
0.0117%
$3.46$38,836-16.91%
2017-12-12SaleChief Commercial Officer
7,424
0.0077%
$3.46$25,691-16.91%
2017-12-12SaleChief Communications Officer
7,022
0.0073%
$3.46$24,304-16.91%
2017-12-12SaleChief Technology Officer
13,092
0.0137%
$3.46$45,302-16.91%
2017-10-30PurchaseChairman & CEO
80,776
0.0835%
$3.61$291,706-2.11%
2017-10-27PurchaseChairman & CEO
119,224
0.1159%
$3.51$418,524-5.18%
2017-04-12PurchaseChairman & CEO
58,912
0.0604%
$3.29$194,109+18.52%
2017-04-10PurchaseChairman & CEO
141,088
0.1464%
$3.37$474,930+16.21%
2017-02-14Purchase10 percent owner
20M
29.1662%
$6.00$120M-14.32%

Insider Historical Profitability

17.93%
ARMEN GARO HSee Remarks
625969
2.9018%
$4.26266+16.59%
WIINBERG ULFdirector
124063
0.5751%
$4.2620<0.0001%
INCYTE CORP10 percent owner
16972968
78.6809%
$4.2615<0.0001%
Sharp Shalinidirector
81311
0.3769%
$4.26215+24.13%
HATSOPOULOS JOHNdirector
65000
0.3013%
$4.2630+179.69%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$19.95B163.8234.4M+13.66%+$2.4B0.37
Deep Track Capital Lp$18.38B150.9531.7M0%+$084.33
Point72 Asset Management$17.47B143.430.11M+151.26%+$10.51B25.54
BlackRock$16.96B139.2929.25M-9.27%-$1.73B0.37
Artal Group S A$9.07B74.4415.63M0%+$039.62
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.